

*Notes

- (1) Changes of important subsidiaries during the period: No
(Change in specified subsidiary with change in scope of consolidation)
- (2) Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial Statements: Yes
(Note) Details are stated on pg. 10 under “Notes on Quarterly Consolidated Financial Statements”
- (3) Change in accounting policies and estimates, correction of prior period errors
- | | |
|---|-----|
| (a) Change in accounting policy with revision of accounting standard: | Yes |
| (b) Change in account policy other than (a): | No |
| (c) Change in accounting estimates: | No |
| (d) Correction of prior period errors: | No |
- (4) Shares issued (common stock)
- | | |
|---|-------------|
| (a)Number of shares issued (including treasury stocks) | |
| 3Q FY2021 | 171,045,418 |
| FY2020 | 171,045,418 |
| (b)Number of treasury stocks | |
| 3Q FY2021 | 10,627,839 |
| FY2020 | 10,593,453 |
| (c)Weighted average of number of shares (cumulative figure for quarter) | |
| 3Q FY2021 | 160,417,739 |
| 3Q FY2020 | 160,346,701 |

*This financial report is not included in quarterly reviews by our external auditors.

*Explanation for the appropriate use of the financial forecast and other comments

Note concerning statements about the future, etc.

The statements about the future, including earnings projections, contained in this report are based on information currently available as well as certain assumptions considered reasonable.

Actual results may vary considerably from these projections owing to a range of factors.

Assumptions upon which the forecast is based and notes on the use of the forecast are stated on pg. 5 under “Disclaimer of Future Outlook Including Consolidated Financial Results Forecast.”

Procedure for obtaining supplementary information on financial results

We plan to hold a conference call for analysts and institutional investors on February 10, 2022.

Materials used in the conference call will be posted on the Company’s website.

Table of Contents

1. Qualitative Information Regarding Quarterly Consolidated Financial Results	2
(1) Business Performance Overview	2
(2) Financial Position	5
(3) Disclaimer on Future Outlook Including Consolidated Financial Results Forecast	5
2. Quarterly Consolidated Financial Statements and Notes	6
(1) Quarterly Consolidated Balance Sheet	6
(2) Quarterly Consolidated Statements of Income and Comprehensive Income	8
Quarterly Consolidated Statement of Income	8
Quarterly Consolidated Statement of Comprehensive Income	9
(3) Notes on Quarterly Consolidated Financial Statements	10
(Notes Related to Going Concern Assumption)	10
(Notes on Substantial Changes in the Amount of Shareholders' Equity)	10
(Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial Statements)	10
(Changes in Accounting Policies)	10
(Quarterly Consolidated Statement of Income)	11
(Segment Information)	12
(Significant Subsequent Events)	14

1. Qualitative Information Regarding Quarterly Consolidated Business Results

(1) Business Performance Overview

1 Performance Overview

During the third quarter of the fiscal year ending March 31, 2022, the challenging circumstances facing the Japanese economy as a result of the novel coronavirus continued a gradual improvement, and economic activity, including consumer spending, showed signs of recovery. However, careful attention must still be paid to the effects of the pandemic on domestic and international economies.

Against this background, the Yakult Group worked to build awareness and understanding of the probiotics that constitute the bedrock of our operations, while striving to communicate the superiority of our products. The Group also sought to improve its performance by enhancing its sales organization, conducting research and development for new products, upgrading its production facilities, and actively engaging in its international and pharmaceutical businesses.

Following these efforts, consolidated net sales for the first nine months of this fiscal year rose 6.9% from the same period of the previous year to 316,539 million yen. Operating profit increased 16.4% to 46,634 million yen, while ordinary profit increased 10.0% to 58,499 million yen. Profit attributable to owners of parent rose 12.5% to 42,022 million yen.

Note that application of the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29 of March 31, 2020, hereinafter “Revenue Recognition Standard”), etc. lowered the reported net sales by 5,705 million yen, but this had no impact on profits.

2 Overview by Segment

Food and Beverages (Japan)

In dairy products, Yakult focused on broadening recognition of the science behind its proprietary living *Lactobacillus casei* strain Shirota* and *Bifidobacterium breve* strain Yakult by conducting grassroots value dissemination initiatives in conjunction with an advertising campaign across all sales channels.

In the home delivery channel, we utilized evidence-based initiatives to encourage continued consumption among existing customers in particular, focusing on the fermented milk drinks *Yakult 1000* and the *Yakult 400* series, including *Yakult 400W*. In addition, we used the increased health awareness resulting from the spread of the novel coronavirus as an opportunity to improve the usability of our Yakult Delivery Net online ordering system and step up efforts to create points of contact for new customers. We also sought to enhance and make better use of our website and other means of communication in an effort to distribute more information about gut health.

As for the retail store channel, we took steps to improve in-store visibility and sales of the *New Yakult* fermented milk drink series by launching packaging with winter-themed designs, as well as conducting consumer campaigns.

In product specific initiatives, we launched *Y1000* in October 2021. This offering in the *Yakult 1000* series was developed for the retail store channel, and we worked to raise its profile primarily by airing a television commercial featuring the Japanese singer Misia. In the same month, we also sought to boost the hard-type yogurt brand *Soful* by launching *Soful Grape* as a limited-time item.

Further to this, we sought to express our appreciation to everybody who had supported the Tokyo Yakult Swallows baseball team by implementing special initiatives to commemorate the team’s victories in the Central League and the Japan Series.

Despite these efforts, consolidated net sales for the Food and Beverages (Japan) segment decreased 2.0% from the same period of the previous fiscal year, totaling 153,893 million yen.

Note that application of the Revenue Recognition Standard had the effect of lowering reported net sales by 17,349 million yen.

* Classified as *Lactocaseibacillus paracasei* strain Shirota as of April 2020.

Food and Beverages (Overseas)

Yakult's operations outside Japan commenced in March 1964 with the establishment of Yakult Taiwan Co., Ltd., and now the manufacture and sale of *Yakult* outside of Japan spans 39 countries and regions centered around 29 companies and one research center, with average daily sales of approximately 28.24 million bottles as of December 2021.

Average daily bottle sales from January to December 2021, which corresponds to the fiscal year for Yakult companies overseas, amounted to approximately 31.64 million bottles.

The impact of the novel coronavirus varies across countries and regions depending on the extent of the infection's spread, as well as the business restrictions implemented by local and national governments, among other factors. We are therefore taking measures appropriate to each location and following the instructions of governmental agencies as we conduct our operations and manufacturing activities.

i. The Americas

Yakult manufactures and sells the fermented milk drink *Yakult* and other products in Brazil, Mexico, and the United States of America.

In these regions, we strived to increase revenue by reinforcing the sales networks for both the home delivery and retail store sales channels.

As a result of these efforts, consolidated net sales in the Food and Beverages (The Americas) segment increased 10.8% from the same period of the previous year to 35,097 million yen.

ii. Asia and Oceania

Yakult manufactures and sells the fermented milk drink *Yakult* and other products in Hong Kong, Singapore, Indonesia, Australia, Malaysia, Vietnam, India, Myanmar, and China, among others, while also importing *Yakult* and other products for sale in the United Arab Emirates (UAE) and other nations.

In China we worked to further reinforce our sales network by increasing the number of sales offices to 50 in August 2021.

In Myanmar, we have temporarily suspended our operations and manufacturing activities in light of the political situation and the spread of the novel coronavirus.

As a result of the above, consolidated net sales in the Food and Beverages (Asia and Oceania) segment rose 9.8% from the same period of the previous year to 99,819 million yen.

iii. Europe

In Europe, Yakult manufactures the fermented milk drink *Yakult* and other products in the Netherlands, and sells them in the Netherlands, Belgium, the United Kingdom, Germany, Austria, Italy, and other countries.

In the European market, where the promotion of probiotics faces strict regulation, we are engaged in a variety of initiatives in our efforts to receive approval for health claims related to our products. Under these difficult circumstances, the Yakult companies in each country aimed for sustainable growth by conducting sales activities tailored to their respective markets.

As a result of these efforts, consolidated net sales in the Food and Beverages (Europe) segment increased 11.9% from the same period of the previous year to 7,068 million yen.

Pharmaceuticals

During the quarter under review, as a means of reducing visits to medical institutions during the

spread of the novel coronavirus, we made use of online meetings among other methods for promoting awareness and the proper use of our products, particularly those specializing in oncology and related fields.

Regarding our mainstay, the antineoplastic drug *Elplat*, as medical institutions are increasingly switching to available generic versions in line with government policy, we boosted initiatives to encourage customers to continue choosing *Elplat* by leveraging our ability to provide relevant information about it, a Company strength as the developer of the original drug. In addition, for the antineoplastic drug *Onivyde*® we have a promotional agreement with Nihon Servier Co., Ltd., and we continued with the same strong promotional activities implemented hitherto, working to boost market penetration and use of the product.

However, our revenue remained virtually unchanged from the previous year due to decreased opportunities to use our products, as the impact of the pandemic prompted a postponement of hospitalizations and operations, a decrease in doctor visits, and other developments. This was compounded by revisions to National Health Insurance drug prices in April 2021, which reduced prices for most of Yakult's pharmaceutical products.

In R&D, we continued to progress with the clinical development of items in our pipeline, including the PI3K inhibitor *duvelisib* [YHI-1702], for which we have an exclusive licensing agreement for development and commercialization in Japan from Secura Bio, Inc. (U.S.), and the HDAC inhibitor *resminostat* [YHI-1001], licensed from 4SC AG (Germany).

Despite the above efforts, however, consolidated net sales in the Pharmaceuticals segment declined 2.7% to 13,197 million yen.

Note that application of the Revenue Recognition Standard had the effect of lowering reported net sales by 486 million yen.

Others

This segment encompasses Yakult's cosmetics manufacturing and sales as well as its professional baseball team operations.

In our cosmetics operations, we worked to help customers realize their inner and outer beauty, and to increase the number of regular users of our cosmetics by focusing on initiatives to disseminate the value of our proprietary moisturizing agent *S.E. (Shirota Essence)*, which is the result of our extensive research on lactic acid bacteria since the Company's foundation.

We sought to provide greater satisfaction for customers by bolstering the *Lactdew* series of basic skin care products through the October 2021 launch of *Lactdew S.E. Cream*, among other examples. We also undertook brand revitalization measures for our *Parabio* series of high-performance basic skin care products, in order to encourage regular use.

Meanwhile, we sought to express appreciation to our customers for their loyalty by implementing special initiatives to commemorate the Tokyo Yakult Swallows baseball team's victories in the Central League and the Japan Series. These special initiatives related to *Yakult Medicated APACOAT S.E. Nanotechnology* toothpaste, among other products.

Our professional baseball operations were again severely impacted by the novel coronavirus, particularly in terms of attendance at games. Nonetheless, the Tokyo Yakult Swallows succeeded in winning both the Central League and the Japan Series with their fans cheering them on. We will continue to work to respond to fans' expectations by maintaining a team that merits their devotion and engaging with them in a greater variety of ways.

As a result of the above factors, consolidated net sales in the Others segment rose 5.8% from the same period of the previous year to 14,825 million yen.

Note that application of the Revenue Recognition Standard had the effect of lowering reported net sales by 544 million yen.

Note: Consolidated sales for each segment include inter-segment sales. Sales figures for each segment do not include consumption tax, etc.

(2) Financial Position

Total assets at the fiscal quarter-end amounted to 673,657 million yen, an increase of 38,555 million yen compared to the previous fiscal year-end, nine months prior.

Net assets increased 45,797 million yen from the previous fiscal year-end to 485,558 million yen. The main factors were an increase in foreign currency translation adjustments due to a weaker yen and an increase in retained earnings due to quarterly profit attributable to owners of parent, outweighing the decline in valuation difference on available-for-sale securities.

The equity to asset ratio was 66.2%, a 2.4 percentage point increase from the previous fiscal year-end.

(3) Disclaimer of Future Outlook Including Consolidated Financial Results Forecast

The forecast in this financial report is based on the information available to management at the time of announcement. Actual operating results may differ from these projections due to various factors in the future.

In many countries, the novel coronavirus has still not abated, but as results remain broadly within the range expected at the current time, earnings forecasts have remained unchanged since their announcement on November 12, 2021.

2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	Fiscal year 2020 As of March 31, 2021	Current period As of December 31, 2021
Assets		
Current assets		
Cash and deposits	176,254	200,009
Notes and accounts receivable-trade	50,307	62,851
Merchandises and finished goods	10,018	9,773
Work in process	2,175	2,359
Raw materials and supplies	15,540	17,517
Others	12,712	12,747
Allowance for doubtful accounts	(209)	(219)
Total current assets	266,800	305,040
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	84,365	83,020
Others, net	118,680	123,606
Total property, plant and equipment	203,045	206,626
Intangible assets		
Software	2,591	2,497
Others	2,789	2,814
Total intangible assets	5,380	5,312
Investments and other assets		
Investment securities	80,238	69,834
Shares of subsidiaries and associates	65,327	71,065
Others	14,396	15,864
Allowance for doubtful accounts	(87)	(86)
Total investments and other assets	159,875	156,678
Total non-current assets	368,301	368,617
Total assets	635,102	673,657

Yakult Honsha Co., Ltd. (2267) Financial Report for the 3rd Quarter of FY2021 ended December 31, 2021

(Millions of yen)

	Fiscal year 2020 As of March 31, 2021	Current period As of December 31, 2021
Liabilities		
Current liabilities		
Notes and accounts payable-trade	22,729	28,812
Short-term loans payable	15,372	5,172
Current portion of long-term loans payable	5,467	5,443
Income taxes payable	4,961	6,651
Provision for bonuses	6,000	3,986
Others	39,016	40,263
Total current liabilities	93,546	90,329
Non-current liabilities		
Long-term loans payable	65,716	61,645
Provision for directors' retirement benefits	368	333
Net defined benefit liability	4,358	4,319
Asset retirement obligations	1,636	1,647
Others	29,715	29,823
Total non-current liabilities	101,794	97,769
Total liabilities	195,341	188,098
Net assets		
Shareholders' equity		
Capital stock	31,117	31,117
Capital surplus	40,937	41,107
Retained earnings	411,359	443,436
Treasury shares	(52,725)	(52,918)
Total shareholders' equity	430,688	462,742
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	24,773	19,293
Foreign currency translation adjustment	(48,482)	(34,346)
Remeasurements of defined benefit plans	(2,028)	(1,779)
Total accumulated other comprehensive income	(25,737)	(16,832)
Non-controlling interests	34,810	39,648
Total net assets	439,761	485,558
Total liabilities and net assets	635,102	673,657

(2) Quarterly Consolidated Statements of Income and Comprehensive Income**Quarterly Consolidated Statement of Income**

(Millions of yen)

	Previous period From April 1, 2020 to December 31, 2020	Current period From April 1, 2021 to December 31, 2021
Net sales	296,057	316,539
Cost of sales	120,866	125,389
Gross profit	175,191	191,149
Selling, general and administrative expenses	135,129	144,514
Operating profit	40,061	46,634
Non-operating income		
Interest income	2,925	2,386
Dividend income	1,880	1,810
Share of profit of entities accounted for using equity method	3,883	5,750
Foreign exchange gains	2,995	1,088
Others	2,399	1,813
Total non-operating income	14,084	12,849
Non-operating expenses		
Interest expenses	573	519
Others	411	466
Total non-operating expenses	984	985
Ordinary profit	53,161	58,499
Extraordinary income		
Gain on sales of non-current assets	216	79
Gain on sales of investment securities	3,753	1,913
Gain on step acquisitions	—	1,180
Others	250	584
Total extraordinary income	4,220	3,757
Extraordinary losses		
Loss on sales of non-current assets	33	938
Loss on retirement of non-current assets	252	281
Loss on valuation of investment securities	892	2
Expense related to a novel coronavirus	1,140	—
Others	245	1
Total extraordinary losses	2,564	1,223
Profit before income taxes	54,817	61,033
Income taxes	13,744	15,691
Profit	41,073	45,342
Profit attributable to non-controlling interests	3,730	3,319
Profit attributable to owners of parent	37,342	42,022

Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	Previous period From April 1, 2020 to December 31, 2020	Current period From April 1, 2021 to December 31, 2021
Profit	41,073	45,342
Other comprehensive income		
Valuation difference on available-for-sale securities	2,396	(5,478)
Foreign currency translation adjustment	(22,484)	15,328
Remeasurements of defined benefit plans, net of tax	404	248
Share of other comprehensive income of entities accounted for using equity method	(130)	379
Total other comprehensive income	(19,813)	10,477
Comprehensive income	21,260	55,819
Comprehensive income attributable to:		
Owners of parent	24,643	50,928
Non-controlling interests	(3,382)	4,891

(3) Notes on Quarterly Consolidated Financial Statements

(Notes Related to Going Concern Assumption)

None.

(Notes on Substantial Changes in the Amount of Shareholders' Equity)

None.

(Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial Statements)

Calculation of Tax Expenses

Tax expenses for the Company and its consolidated subsidiaries in Japan are calculated by multiplying profit before income taxes for the third quarter under review by the reasonably estimated effective tax rate after applying tax effect accounting to the profit before income taxes for the current consolidated fiscal year, including the third quarter under review.

In addition, income taxes–deferred are included in income taxes.

(Changes in Accounting Policies)

Application of Accounting Standard for Revenue Recognition

With application of the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29 of March 31, 2020, hereinafter “Revenue Recognition Standard”), etc. from the beginning of the first quarter of the current fiscal year, revenue is now recognized as the amount expected to be received in exchange for goods or services at the time control of the promised good or service is transferred to the customer.

In the Food and Beverages (Japan) segment, this change means that for sales of equipment and materials, for which the gross amount was previously recognized as revenue, the net amount is now recognized as revenue, based on determining roles in provision of goods or services to customers (direct or agent transactions). In addition, distribution center fees paid in this segment to mass retailers, etc., and incentive fees or other consideration paid to customers in this segment and in the Pharmaceuticals and Others segments, which were previously accounted for as selling, general and administrative expenses, are now accounted for by deducting them from net sales.

Note also that application of the Revenue Recognition Standard was made from the beginning of the first quarter of the current fiscal year in accordance with the transitional measure indicated in the proviso to Paragraph 84 of the Revenue Recognition Standard.

As a result, sales in the third quarter consolidated cumulative period were lower by 5,705 million yen, cost of sales was lower by 2,968 million yen, and selling, general and administrative expenses were lower by 2,736 million yen. There was no impact on operating profit, ordinary profit, quarterly profit before income taxes, or retained earnings (balance at beginning of year).

In accordance with the transitional measure indicated in Paragraph 28-15 of the Accounting Standard for Quarterly Financial Reporting (ASBJ Statement No. 12 of March 31, 2020), information on the classification of relevant revenues from contracts with customers is not given.

Application of Accounting Standard for Fair Value Measurement

Application of the Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30 of July 4, 2019; hereinafter, “Fair Value Measurement Standard”) was made from the beginning of the first quarter of the current fiscal year. In accordance with the transitional measures indicated in Paragraph 19 of the Fair Value Measurement Standard and in Paragraph 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10 of July 4, 2019), the new accounting policies stipulated in the Fair Value Measurement Standard, etc. are to be applied from now on. There is no impact from these changes on the quarterly consolidated financial statements.

(Quarterly Consolidated Statement of Income)

Gain (Loss) on Step Acquisition (Extraordinary Income)

This income occurred because affiliated company Yakult Toyama Sales Co., Ltd. became a consolidated subsidiary through an increase in equity ratio.

(Segment Information)

I The third quarter of FY2020 (April 1 to December 31, 2020)

1.Net sales and profit (loss) in each reportable segment

(Millions of yen)

	Food and Beverages			
	Japan	The Americas	Asia and Oceania	Europe
Net sales				
Net sales to external customers	141,158	31,688	90,912	6,319
Intersegment net sales or transfers	15,903	—	—	—
Total	157,061	31,688	90,912	6,319
Segment profit (loss)	18,285	8,607	24,563	771

	Pharmaceuticals	Others	Adjustments	Consolidated results
Net sales				
Net sales to external customers	13,568	12,410	—	296,057
Intersegment net sales or transfers	—	1,596	(17,499)	—
Total	13,568	14,006	(17,499)	296,057
Segment profit (loss)	356	688	(13,210)	40,061

Notes: 1. Adjustments are as follows.

The (13,210) million yen of adjustment in segment profit (loss) includes (9,558) million yen of corporate expenses not allocated to specific reportable segments. Corporate expenses include those of administrative divisions of the Company, such as the general affairs department, that cannot be attributed to any specific reportable segments.

2. Segment profits are adjusted with operating profit under the quarterly consolidated statements of income.
3. Countries / regions in each geographic segment outside Japan.

- | | |
|----------------------|--|
| (1) The Americas | Mexico, Brazil, The United States of America |
| (2) Asia and Oceania | Hong Kong, China, Indonesia, Singapore, Malaysia, Australia, India, Vietnam, The United Arab Emirates, Myanmar |
| (3) Europe | The Netherland, The United Kingdom, Germany, Belgium, Austria, Italy |

II The third quarter of FY2021 (April 1 to December 31, 2021)

1. Net sales, profit (loss) and disaggregated revenue in each reportable segment

(Millions of yen)

	Food and Beverages			
	Japan	The Americas	Asia and Oceania	Europe
Net sales				
Revenue from contracts with customers	148,162	35,097	99,819	7,068
Other revenues	—	—	—	—
Net sales to external customers	148,162	35,097	99,819	7,068
Intersegment net sales or transfers	5,731	—	—	—
Total	153,893	35,097	99,819	7,068
Segment profit (loss)	22,123	9,457	23,423	894

	Pharmaceuticals	Others	Adjustments	Consolidated results
Net sales				
Revenue from contracts with customers	13,197	13,193	—	316,539
Other revenues	—	—	—	—
Net sales to external customers	13,197	13,193	—	316,539
Intersegment net sales or transfers	—	1,632	(7,363)	—
Total	13,197	14,825	(7,363)	316,539
Segment profit (loss)	2,309	(320)	(11,252)	46,634

Notes: 1. Adjustments are as follows.

The (11,252) million yen adjustment in segment profit (loss) includes (7,118) million yen of corporate expenses not allocated to specific reportable segments. Corporate expenses include those of administrative divisions of the Company, such as the general affairs department, that cannot be attributed to any specific reportable segments. Starting from the first quarter of the current fiscal year, based on the long-term vision formulated in this term, the details of corporate expenses have been subjected to a review, with some of them being attributed to individual segments. Compared to the previous method, this change reduced the reported profits in each of the Food and Beverages regional segments by 1,707 million yen (Japan), 250 million yen (The Americas), 803 million yen (Asia and Oceania), and 57 million yen (Europe), while the adjustment amount for corporate expenses was 2,818 million yen lower.

2. Segment profits are adjusted with operating profit under the quarterly consolidated statements of income.
3. Countries / regions in each geographic segment outside Japan.

- (1) The Americas Mexico, Brazil, The United States of America
- (2) Asia and Oceania Hong Kong, China, Indonesia, Singapore, Malaysia, Australia, India, Vietnam, The United Arab Emirates, Myanmar
- (3) Europe The Netherland, The United Kingdom, Germany, Belgium, Austria, Italy

2. Matters related to changes in reportable segments, etc.

As noted regarding accounting policy changes, the Revenue Recognition Standard was applied from the start of the first quarter of the current fiscal year, changing the accounting method regarding revenue recognition, so that the method of accounting for segment net sales was similarly changed.

Compared to the previous method, this change reduced reported net sales for the third quarter of the current fiscal year in the Food and Beverages (Japan) segment by 17,349 million yen, in the Pharmaceuticals segment by 486 million yen, and in the Others segment by 544 million yen. There is no impact from these changes on segment profits.

(Significant Subsequent Events)

Share Repurchase as Treasury Stock

At a meeting of its Board of Directors held on February 10, 2022, the Company resolved matters pertaining to a share repurchase pursuant to Article 459, Paragraph 1 of the Companies Act and Article 36 of its Articles of Incorporation.

(1) Reasons for share repurchase

- To strengthen shareholder returns and improve capital efficiency

To further improve its corporate value going forward, the Company believes that a capital policy is an important factor in addition to the achievement of Yakult Group Global Vision 2030. By comprehensively taking into consideration the investment funds required for future business growth as well as the trend in the stock market, the Company has judged that effectively utilizing its assets alongside strengthening shareholder returns and improving capital efficiency, while maintaining a strong financial foundation resilient enough to withstand the changes in the environment, would contribute to improving its corporate value, and as such, decided to purchase its own shares as treasury stock.

(2) Details of matters pertaining to repurchase

(i) Class of shares to be repurchased	Common stock of the Company
(ii) Total number of shares to be repurchased	5,500,000 shares (maximum) (3.43% of total number of issued and outstanding shares (excluding treasury stock))
(iii) Aggregate repurchase price	¥30 billion (maximum)
(iv) Period of share repurchase	From Monday, February 14, 2022 to Friday, August 12, 2022
(v) Method of share repurchase	Open market purchase on the Tokyo Stock Exchange

Reference: Status of shares held as treasury stock as of January 31, 2022

- Total number of issued and outstanding shares (excluding treasury stock):	160,493,762
- Number of shares held as treasury stock:	10,551,656